Hexima/Monsanto wheat research deal
The Australian biotechnology company, Hexima (Melbourne, Victoria), has licensed its anti-fungal protein technology to Monsanto for the development of disease-resistant wheat. The deal includes a future option for commercialisation depending on research results. The research is at an early stage, but has shown initial success in field trials of other crops over several seasons, Hexima points out. The deal is “another important step in commercialising the technology across all major crops globally”, says Hexima’s executive chairman, Ross Dobinson. The company agreed a deal with DuPont in 2008 to develop a range of genetically modified disease-resistant crops ( Agrow No 550, p 1).